Morgan Stanley maintains Recursion Pharmaceuticals at Equal-Weight, lowers price target to $5.60 from $5.90
Morgan Stanley kept Recursion Pharmaceuticals at Equal-Weight but reduced its price target to $5.60 from $5.90, a 5.1% cut. This implies a 105.9% upside from the Nov 17 close of $2.72.
How this was made

The 30-second read
Why it matters
A lower target can influence short-term positioning and expectations, but unchanged rating suggests the analyst does not see a major deterioration requiring a downgrade.
Market read
Traders may use the target cut to reassess near-term valuation expectations, but it is unlikely to drive a major repricing without additional new fundamentals.
What to watch
Price-target changes can lag fundamentals; without new trial/regulatory information, traders may discount the note relative to broader biotech risk appetite.
Background
The article summarizes an analyst action from Morgan Stanley on Recursion Pharmaceuticals, including a maintained rating and a reduced price target.
Ticker impact
Morgan Stanley maintained Recursion Pharmaceuticals at Equal-Weight and cut its price target to $5.60 from $5.90, a 5.1% reduction.
Likely mild downward pressure or limited upside as traders adjust expectations to the reduced target, with muted follow-through given no rating change.
This is a single-bank price-target cut without an upgrade or downgrade, so it is more sentiment-adjustment than a fundamental catalyst.
Market effects
Limited read-through to biotech/AI-drug discovery peers because it is a single-name target adjustment with no new clinical or regulatory data.
Minimal, as the catalyst is company-specific analyst commentary.
Low, no cross-market policy or macro linkage is described.
Counterpoint
Because the rating stays Equal-Weight, the market may treat the target cut as incremental and focus on upcoming company-specific catalysts (trials, approvals, partnerships).
Key entities
- companyRecursion Pharmaceuticals
Subject of the analyst note, rated Equal-Weight with a lowered price target.
- analyst_firmMorgan Stanley
Maintained the rating and reduced the price target.



